An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 26 Sep 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 22 Sep 2016 Planned End Date changed from 1 Oct 2016 to 1 Dec 2018.